Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a ...

Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

Explore how nutrition plays a crucial role in cancer prevention, treatment, and recovery, emphasizing the power of a balanced ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) effectively at boost the ...

Cancer takes a devastating toll on the body—but the psychological burden can be just as profound. Many patients, even those with a long history of resilience and optimism, experience notable emotional ...

A cruel consequence of advanced cancer is the profound apathy many patients experience as they lose interest in once-cherished activities. This symptom is part of a syndrome called cachexia, which ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...